C-NJL8BioChange ltd
foam scaffold, tissue repair, regenerative medicine
repairingtissue engineered
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NJL8
C-NJL8C-NJL8foam scaffold, tissue repair, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
BioChange ltd foam scaffold, tissue repair, regenerative medicine
BioChange is a biotech company developing CellFoam, a biodegradable and biocompatible foam scaffold designed to support three-dimensional tissue repair. Its technology is commercialized for veterinary use and is moving toward first clinical approval in humans focused on periodontitis. The company lists human, dental, aesthetic, neurology, and veterinary applications, supported by a portfolio of granted and pending patents.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
BioChange ltd — Near-term readout · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (2 programs at approved).…
Source: Deterministic